Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex

[1]  Bita Moghaddam,et al.  Characterization of Excitatory Amino Acid Modulation of Dopamine Release in the Prefrontal Cortex of Conscious Rats , 1996, Journal of neurochemistry.

[2]  S. Potkin,et al.  Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[3]  B. Moghaddam,et al.  NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[4]  J. Soghomonian,et al.  MK-801 decreases striatal and cortical GAD65 mRNA levels , 1995, Neuroreport.

[5]  P. Goldman-Rakic,et al.  Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. , 1995, Archives of general psychiatry.

[6]  J. Kleinman,et al.  Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. , 1995, Archives of general psychiatry.

[7]  P. Goldman-Rakic,et al.  Modulation of memory fields by dopamine Dl receptors in prefrontal cortex , 1995, Nature.

[8]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[9]  T. Nishikawa,et al.  Dizocilpine (MK-801) elicits a tetrodotoxinsensitive increase in extracellular release of dopamine in rat medial frontal cortex , 1995, Neurochemistry International.

[10]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[11]  U. Ungerstedt,et al.  Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid. , 1994, European journal of pharmacology.

[12]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[13]  B. Weiss,et al.  Dopaminergic and glutamatergic blocking drugs differentially regulate glutamic acid decarboxylase mRNA in mouse brain. , 1994, Brain research. Molecular brain research.

[14]  N. Tashiro,et al.  Effect of phenycyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study , 1994, Brain Research.

[15]  V. Klimek,et al.  MK-801 elevates the etracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors , 1993, Brain Research.

[16]  Sohee Park,et al.  Schizophrenics show spatial working memory deficits. , 1992, Archives of general psychiatry.

[17]  W. Löscher,et al.  The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. , 1992, European journal of pharmacology.

[18]  A. Deutch,et al.  Dopaminergic mechanisms in the pathogenesis of schizophrenia 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  O. Paulsen,et al.  Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[20]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[21]  W. Löscher,et al.  The N-methyl-d-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats , 1991, Neuroscience Letters.

[22]  J. Warter,et al.  Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat , 1991, Neuroscience Letters.

[23]  R. Waziri,et al.  Evidence of glutamatergic deficiency in schizophrenia , 1991, Neuroscience Letters.

[24]  W. Turski,et al.  Excitatory amino acid antagonists and memory: Effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks , 1990, Neuropharmacology.

[25]  P. Slater,et al.  Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia , 1989, Journal of neurochemistry.

[26]  U. Ungerstedt,et al.  Fast HPLC Estimation of γ‐Aminobutyric Acid in Microdialysis Perfusates: Effect of Nipecotic and 3‐Mercaptopropionic Acids , 1988, Journal of neurochemistry.

[27]  D. Weinberger,et al.  Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. , 1988, Archives of general psychiatry.

[28]  T. Honoré,et al.  Phencyclidine analogues inhibit NMDA-stimulated [3H]GABA release from cultured cortex neurons. , 1987, European journal of pharmacology.

[29]  L. DeLisi,et al.  Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. , 1987, Life sciences.

[30]  T. Robinson,et al.  Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis , 1986, Brain Research Reviews.

[31]  A. Thomson,et al.  An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? , 1985, Nature.

[32]  M. Taylor,et al.  Cognitive impairment in schizophrenia. , 1984, The American journal of psychiatry.

[33]  D. J. Smith,et al.  Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines , 1981, Neuropharmacology.

[34]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[35]  U. Ungerstedt,et al.  Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. , 1971, Acta physiologica Scandinavica. Supplementum.

[36]  M. Toru,et al.  Excitatory amino acids: implications for psychiatric disorders research. , 1994, Life sciences.

[37]  Babu Subramanyam,et al.  MONITORING MOLECULES IN NEUROSCIENCE , 1991 .

[38]  J. Lieberman,et al.  Dopaminergic mechanisms in idiopathic and drug-induced psychoses. , 1990, Schizophrenia bulletin.

[39]  R. Kahn,et al.  The role of serotonin in schizophrenia. , 1988, Schizophrenia bulletin.

[40]  H. Meltzer,et al.  Psychopharmacology : the third generation of progress , 1987 .

[41]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .